US Senate Majority Leader Chuck Schumer asks the FDA to investigate Prime energy drink; Washington state sees hefty fine for failing to provide mental health resources to incarcerated individuals; a new rule would require companies to disclose use of certain “forever” chemicals.
Despite the need for improved eczema therapies and a rapid increase in available clinical trials, participation remains low.
More attention should be paid to prevent acne scarring and address the psychosocial consequences associated with it, authors argue.
Symptoms initially pointed to toxic alcohol ingestion.
There is no approved treatment for chronic hepatitis D virus infection in the United States, but recent phase 3 trial results showed encouraging safety and efficacy associated with bulevirtide.
The patient in this case experienced significant muscle weakness after emerging from anesthesia.
New data from AIDSVu show significant disparities in the usage of HIV pre-exposure prophylaxis (PrEP). Black and Hispanic/Latinx Americans are underrepresented among PrEP users, despite accounting for a significant portion of new HIV diagnoses.
The US government has set a goal of achieving viral clearance in 80% of patients by 2030.
Investigators stress the importance of ongoing research on the association between depression and pain in patients with sickle cell disease (SCD).
Martin Griesshammer, MD, PhD, Johannes Wesling University Clinic, discusses past and current efforts to improve treatment options for patients with polycythemia vera.
Investigators said it is important for clinicians to interpret scans with knowledge of case-specific context for patients with diffuse large B-cell lymphoma (DLBCL).
The condition was seen in a 75-year-old female patient with a history of epilepsy and hypertension.
The study investigated event rates for several outcomes in the year following a first hospitalization for heart failure (HF), including implementation of guideline-directed medical therapy (GDMT).
Obstructive sleep apnea (OSA) could contribute to mood worsening in patients with OSA and chronic insomnia (CI).
Noortje van Herwaarden, MD, PhD, discusses the results of a 10-year follow-up from the DRESS study and how it informs use of disease activity-guided dose optimization in treatment of rheumatoid arthritis.
The cross-sectional study found that higher childhood neighborhood area deprivation index (ADI), obesity, age, sex, and length of Medicaid benefit coverage are all associated with a primary hypertension diagnosis among youth residing in Delaware.
In a disease such as chronic myeloid leukemia (CML), shared treatment decision-making between providers and patients is key, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.
A new study has found that initial visits and the number of viral load tests decreased during the COVID-19 pandemic but viral suppression and hospitalizations remained stable.
Rates of next-generation sequencing (NGS) more than doubled once a nurse navigation program was implemented.
A new proposal from the Biden administration would place more restrictions on certain health insurance plans as part of an initiative to cut costs; Eli Lilly’s obesity treatment retatrutide appears to help lessen liver fat content; Earth’s hottest day on record calls into question what temperatures humans can safely tolerate.
Once-daily venous thromboembolism (VTE) prophylaxis with 10 mg of rivaroxaban for either 7 or 28 days after bariatric surgery was found to be effective and safe.
Researchers addressed the link between mental health conditions and chronic cough severity to help physicians personalize their treatment plans.
A well-regarded tool for predicting prognosis in myelodysplastic syndromes is updated to incorporate mutations and tested with real-world data.
The rare autoimmune disorder generalized myasthenia gravis can cause muscle weakness in the limbs and face.
Improving culturally responsive care and practicing cultural humility can help health care providers deliver equitable care for all patients living with multiple myeloma (MM).
The full approval follows an accelerated approval from January 2023 and was based on a confirmatory trial, which found lecanemab slowed disease progression compared with placebo.
Data included in this analysis are from the Respiratory Health in Northern Europe study, and they include asthma status, asthma-like symptoms, and other respiratory symptoms.
A predictive artificial intelligence (AI) biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer was validated in a recent study published in NEJM Evidence.
Investigators found no significant impact on survival, however.
